BFM
STOK icon

Boothbay Fund Management’s Stoke Therapeutics STOK Stock Holding History

Boothbay Fund Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64,900
Closed -$833K – 2428
2022
Q3 		$833K Buy
+64,900
New +$1.03M 0.02% 965
2021
Q2 		– Sell
-121
Closed -$470K – 2101
2021
Q1 		$470K Buy
+121
New +$6.89K 0.02% 978

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boothbay Fund Management's STOK Position: Q2 2026 in Review

Boothbay Fund Management increased its Stoke Therapeutics (STOK) stake by 71% in Q2 2026, buying an estimated $1.08M and bringing the position to 80,968 shares worth $2.65M. The position accounts for 0.03% of the portfolio, ranked #590.

Boothbay Fund Management first reported a position in STOK in Q1 2022 and has held it in 5 quarters since. The position peaked at $4.33M in Q1 2022. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Boothbay Fund Management held 80,968 shares of Stoke Therapeutics worth $2.65M as of Q2 2026.
  • Boothbay Fund Management bought 33,661 Stoke Therapeutics shares in Q2 2026, an estimated $1.08M.
  • Stoke Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #590 holding.
  • Boothbay Fund Management first reported a position in Stoke Therapeutics in Q1 2022 and has held it in 5 quarters since.
  • Boothbay Fund Management's Stoke Therapeutics position peaked at $4.33M in Q1 2022.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.